ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLC

ALEX: alectinib is the best first-line therapy available for ALK-positive NSCLC

VJOncology

1 year
98 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ross Camidge, MD, PhD, of the University of Colorado, Denver, CO, gives an update on the Phase III ALEX trial (NCT02075840), which compared ALK inhibitors alectinib and crizotinib as first-line therapies for advanced non-small cell lung cancer (NSCLC). In addition to alectinib, Dr Camidge discusses the second-generation ALK inhibitors brigatinib, ensartinib and lorlatinib.
Up Next Autoplay